Management of chronic pain in cancer survivors

Cancer Journal

Volumn 14, Issue 6, 2008, Pages 401-409

  Levy, Michael H ^a,b   Chwistek, Marcin ^a   Mehta, Rohtesh S ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NONE

Author keywords

Neoplasms; Neuropathic pain; Opioids; Pain; Quality of life; Review; Survivorship; Therapeutics

Indexed keywords

ANALGESIC AGENT; BACLOFEN; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; CISPLATIN; CLONAZEPAM; CLONIDINE; DESIPRAMINE; DOCETAXEL; DULOXETINE; FENTANYL; GABAPENTIN; GLUCOCORTICOID; HALOPERIDOL; LOCAL ANESTHETIC AGENT; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OMEGA CONOTOXIN MVIIA; OPIATE; OXALIPLATIN; PACLITAXEL; PREGABALIN; PROCHLORPERAZINE; VENLAFAXINE; VINBLASTINE; VINCRISTINE;

ACCESSORY NERVE DISEASE; ARTICLE; ASEPTIC NECROSIS; BLADDER CANCER; BONE NECROSIS; BONE PAIN; BRACHIAL PLEXUS INJURY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CERVICOBRACHIAL NEURALGIA; CHEST TIGHTNESS; CHRONIC PAIN; COMPRESSION FRACTURE; CONNECTIVE TISSUE FIBROSIS; CONSTIPATION; CYSTITIS; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSURIA; ENTERITIS; FEMUR HEAD NECROSIS; FRAGILITY FRACTURE; FROZEN SHOULDER; HEAD AND NECK CANCER; HEPATOSPLENOMEGALY; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPOGONADISM; INTERVENTION STUDY; JAW OSTEONECROSIS; LUNG CANCER; LUNG FIBROSIS; LYMPHADENOPATHY; MASTALGIA; NAUSEA; NERVE COMPRESSION; NEURALGIA; NEUROMA; NEUROPATHIC PAIN; NEUROPATHY; ODYNOPHAGIA; OSTEOARTHRITIS; OSTEOPOROSIS; PELVIS PAIN SYNDROME; PERICARDITIS; PERIPHERAL NEUROPATHY; PHANTOM PAIN; PHYSIOTHERAPY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RECTUM CANCER; SARCOMA; SEDATION; SHOULDER PAIN; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SOCIAL PSYCHOLOGY; SOMATIC PAIN; SPINAL CORD DISEASE; THORAX PAIN; UROGENITAL TRACT CANCER; UTERUS CANCER; VASCULAR FIBROSIS; VISCERAL PAIN;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES; PAIN; PAIN, POSTOPERATIVE; PALLIATIVE CARE; QUALITY OF LIFE; RADIOTHERAPY; SURGICAL PROCEDURES, OPERATIVE; SURVIVORS;

EID: 58149260023     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31818f5aa7     Document Type: Article

References (139)

1. Centers for Disease Control and Prevention (CDC). Cancer survivorship-United States, 1971-2001. MMWR Morb Mortal Wkly Rep. 2004; 53:526-529.
2. Alfano CM, Rowland JH. Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J. 2006;12:432-443.
3. Foley KM. Controlling cancer pain. Hosp Pract (Minneap). 2000;35: 101-108, 111-112.
4. Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175:265-275.
5. Wall PD, McMahon SB, Koltzenburg M. Wall and Melzack's Textbook of Pain. 5th ed. Philadelphia: Elsevier/Churchill Livingstone 2006:1239, xviii.
6. Dubner R, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 1992;15:96-103.
7. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002; 5(Suppl):1062-1067.
8. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765-1769.
9. Couture R, Harrisson M, Vianna RM, et al. Kinin receptors in pain and inflammation. Eur J Pharmacol. 2001;429:161-176.
10. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol. 1999;57:1-164.
11. Ji RR, Kohno T, Moore KA, et al. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003; 26:696-705.
12. Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology. 1995;34:1219-1237.
13. Rogers ML, Duffy JP. Surgical aspects of chronic post-thoracotomy pain. Eur J Cardiothorac Surg. 2000;18:711-716.
14. Tasmuth T, von Smitten K, Hietanen P, et al. Pain and other symptoms after different treatment modalities of breast cancer. Ann Oncol. 1995; 6:453-459.
15. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27-46.
16. DeAngelis LM, Gnecco C, Taylor L, et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer. 1991;67:2241-2246.
17. Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000;93:1123-1133.
18. Benedetti F, Vighetti S, Ricco C, et al. Neurophysiologic assessment of nerve impairment in posterolateral and muscle-sparing thoracotomy. J Thorac Cardiovasc Surg. 1998;115:841-847.
19. Tasmuth T, Kataja M, Blomqvist C, et al. Treatment-related factors predisposing to chronic pain in patients with breast cancer-a multivariate approach. Acta Oncol. 1997;36:625-630.
20. Smith J, Thompson JM. Phantom limb pain and chemotherapy in pediatric amputees. Mayo Clin Proc. 1995;70:357-364.
21. Dajczman E, Gordon A, Kreisman H, et al. Long-term postthoracotomy pain. Chest. 1991;99:270-274.
22. Steegers MA, Snik DM, Verhagen AF, et al. Only half of the chronic pain after thoracic surgery shows a neuropathic component. J Pain. 2008;9:955-961.
23. Foley KM. Pain syndromes in patients with cancer. Med Clin North Am. 1987;71:169-184.
24. Jung BF, Ahrendt GM, Oaklander AL, et al. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain. 2003;104:1-13.
25. Dijkstra PU, Rietman JS, Geertzen JH. Phantom breast sensations and phantom breast pain: a 2-year prospective study and a methodological analysis of literature. Eur J Pain. 2007;11:99-108.
26. Kroner K, Krebs B, Skov J, et al. Immediate and long-term phantom breast syndrome after mastectomy: incidence, clinical characteristics and relationship to pre-mastectomy breast pain. Pain. 1989;36:327-334.
27. Stevens PE, Dibble SL, Miaskowski C. Prevalence, characteristics, and impact of postmastectomy pain syndrome: an investigation of women's experiences. Pain. 1995;61:61-68.
28. Rosso R, Scelsi M, Carnevali L. Granular cell traumatic neuroma: a lesion occurring in mastectomy scars. Arch Pathol Lab Med. 2000; 124: 709-711.
29. Watson CP, Evans RJ, Watt VR. The post-mastectomy pain syndrome and the effect of topical capsaicin. Pain. 1989;38:177-186.
30. Wallace MS, Wallace AM, Lee J, et al. Pain after breast surgery: a survey of 282 women. Pain. 1996;66:195-205.
31. Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg. 1993;36:315-320.
32. Nikolajsen L, Ilkjaer S, Kroner K, et al. The influence of preamputation pain on postamputation stump and phantom pain. Pain. 1997;72:393-405.
33. Nikolajsen L, Ilkjaer S, Christensen JH, et al. Randomised trial of epidural bupivacaine and morphine in prevention of stump and phantom pain in lower-limb amputation. Lancet. 1997;350:1353-1357.
34. Schug SA, Burrell R, Payne J, et al. Pre-emptive epidural analgesia may prevent phantom limb pain. Reg Anesth. 1995;20:256.
35. Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. Pain. 1984;18:83-95.
36. Nikolajsen L, Jensen TS. Phantom limb pain. Curr Rev Pain. 2000;4: 166-170.
37. Ehde DM, Czerniecki JM, Smith DG, et al. Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain after lower limb amputation. Arch Phys Med Rehabil. 2000;81:1039-1044.
38. Talmi YP, Horowitz Z, Pfeffer MR, et al. Pain in the neck after neck dissection. Otolaryngol Head Neck Surg. 2000;123:302-306.
39. Krause HR, Bremerich A, Herrmann M. The innervation of the trapezius muscle in connection with radical neck-dissection. An anatomical study. J Craniomaxillofac Surg. 1991;19:87-89.
40. Johansson S, Svensson H, Denekamp J. Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2002;52:1207-1219.
41. Mondrup K, Olsen NK, Pfeiffer P, et al. Clinical and electrodiagnostic findings in breast cancer patients with radiation-induced brachial plexus neuropathy. Acta Neurol Scand. 1990;81:153-158.
42. Olsen NK, Pfeiffer P, Mondrup K, et al. Radiation-induced brachial plexus neuropathy in breast cancer patients. Acta Oncol. 1990;29:885-890.
43. Svensson H, Westling P, Larsson LG. Radiation-induced lesions of the brachial plexus correlated to the dose-time-fraction schedule. Acta Radiol Ther Phys Biol. 1975;14:228-238.
44. Kori SH. Diagnosis and management of brachial plexus lesions in cancer patients. Oncology (Williston Park). 1995;9:756-760; discussion 765.
45. Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1992;23:915-923.
46. Schierle C, Winograd JM. Radiation-induced brachial plexopathy: review. Complication without a cure. J Reconstr Microsurg. 2004;20: 149-152.
47. Upton AR, McComas AJ. The double crush in nerve entrapment syndromes. Lancet. 1973;2:359-362.
48. Stryker JA, Sommerville K, Perez R, et al. Sacral plexus injury after radiotherapy for carcinoma of cervix. Cancer. 1990;66:1488-1492.
49. Schultheiss TE, Stephens LC. Invited review: permanent radiation myelopathy. Br J Radiol. 1992;65:737-753.
50. Nussbaum ML, Campana TJ, Weese JL. Radiation-induced intestinal injury. Clin Plast Surg. 1993;20:573-580.
51. Perez CA, Grigsby PW, Lockett MA, et al. Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. Int J Radiat Oncol Biol Phys. 1999;44:855-866.
52. Ogino I, Okamoto N, Ono Y, et al. Pelvic insufficiency fractures in postmenopausal woman with advanced cervical cancer treated by radiotherapy. Radiother Oncol. 2003;68:61-67.
53. Minsky BD, Cohen AM. Minimizing the toxicity of pelvic radiation therapy in rectal cancer. Oncology (Williston Park). 1988;2:21-25, 28-29.
54. Merrick GS, Butler WM, Wallner KE, et al. Brachytherapy-related dysuria. BJU Int. 2005; 95:597-602.
55. Merrick GS, Butler WM, Wallner KE, et al. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:979-985.
56. Wallner K, Elliott K, Merrick G, et al. Chronic pelvic pain following prostate brachytherapy: a case report. Brachytherapy. 2004;3:153-158.
57. Parker RG, Berry HC. Late effects of therapeutic irradiation on the skeleton and bone marrow. Cancer. 1976;37(2 suppl): 1162-1171.
58. Massin P, Duparc J. Total hip replacement in irradiated hips. A retrospective study of 71 cases. J Bone Joint Surg Br. 1995;77:847-852.
59. Grigsby PW, Roberts HL, Perez CA. Femoral neck fracture following groin irradiation. Int J Radiat Oncol Biol Phys. 1995;32:63-67.
60. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116-126.
61. Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol. 2007;62:148-152.
62. Kademani D, Koka S, Lacy MQ, et al. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc. 2006;81:1100-1103.
63. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-376.
64. Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist. 2008;13:187-195.
65. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006; 11:1121-1131.
66. Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol. 2008;179:414-423.
67. Diel IJ, Fogelman I, Al-Nawas B, et al. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol. 2007;64:198-207.
68. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-441.
69. Cavanna L, Bertè R, Arcari A, et al. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Intern Med. 2007;18:417-422.
70. Lopez AM, Pena MA, Hernández R, et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005; 16:707-711.
71. Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000;86:449-452.
72. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136-139; discussion 139.
73. Bruning PF, Pit MJ, de Jong-Bakker M, et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 1990;61:308-310.
74. Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: a meta-analytic review. Pain. 1992;49:221-230.
75. Robbins H, Gatchel RJ, Noe C, et al. A prospective one-year outcome study of interdisciplinary chronic pain management: compromising its efficacy by managed care policies. Anesth Analg. 2003;97:156-162, table of contents.
76. Gonzales GR, Elliott KJ, Portenoy RK, et al. The impact of a comprehensive evaluation in the management of cancer pain. Pain. 1991 ;47: 141-144.
77. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-1534.
78. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA. 2005;293:3043-3052.
79. Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71-78.
80. Foley KM. Opioids and chronic neuropathic pain. N Engl J Med. 2003;348:1279-1281.
81. Rowbotham MC, Twilling L, Davies PS. et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003; 348:1223-1232.
82. Huse E, Larbig W, Flor H, et al. The effect of opioids on phantom limb pain and cortical reorganization. Pain. 2001;90:47-55.
83. Raja SN. Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized. placebo-controlled trial. Neurology. 2002;59:1015-1021.
84. Levy MH, Samuel TA. Management of cancer pain. Semin Oncol. 2005;32:179-193.
85. Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain. 1998;2:239-249.
86. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Svmptom Manage. 1997;13:254-261.
87. Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004;22:185-192.
88. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9:595-612.
89. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med. 2008;9:315-344.
90. Shaiova L. The role of methadone in the treatment of moderate to severe cancer pain. Support Cancer Ther. 2005;2:176-180.
91. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev. 2004:CD003971.
92. Ballantyne JC. Opioid misuse in oncology pain patients. Curr Pain Headache Rep. 2007;11:276-282.
93. Passik SD, Kirsh KL. Managing pain in patients with aberrant drugtaking behaviors. J Support Oncol. 2005;3:83-86.
94. McGeeney BE. Adjuvant agents in cancer pain. Clin J Pain. 2008; 24(suppl 10):S14-S20.
95. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007:CD005454.
96. Rasmussen PV, Jensen TS, Sindrup SH, et al. TDM-based imipramine treatment in neuropathic pain. Ther Drug Monit. 2004;26:352-360.
97. Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22:417-442.
98. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathiccancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22:2909-2917.
99. Ross JR. Goller K, Hardy J, et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective. open-label study. J Palliat Med. 2005;8:1118-1126.
100. Keskinbora K, Pekel AF. Aydinli 1. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manage. 2007;34:183-189.
101. Dobecki DA, Schocket SM, Wallace MS. Update on pharmacotherapy guidelines for the treatment of neuropathic pain. Curr Pain Headache Rep. 2006;10:185-190.
102. Jensen TS, Finnerup NB. Management of neuropathic pain. Curr Opin Support Palliat Care. 2007;1:126-131.
103. Stacey BR, Swift JN. Pregabalin for neuropathic pain based on recent clinical trials. Curr Pain Headache Rep. 2006;10:179-184.
104. Varghese A, Murphy B, McCluskey DR, et al. Bone marrow suppression secondary to carbamazepine. Br J Clin Pract. 1989;43:302-304.
105. Hugel H, Ellershaw JE, Dickman A. Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage. 2003;26:1073-1074.
106. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005:CD001133.
107. Harmer JP, Larson BS. Pain relief from baclofen analgesia in a neuropathic pain patient who failed opioid and pharmacotherapy: case report. J Pain Palliat Care Pharmacother. 2002;16:61-64.
108. Knotkova H, Pappagallo M. Adjuvant analgesics. Med Clin North Am. 2007;91:113-124.
109. McCleane G. Pharmacological management of neuropathic pain. CNS Drugs. 2003;17:1031-1043.
110. Roelofs PD, Deyo RA, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine. 2008;33: 1766-1774.
111. Herndon CM, Hutchison RW, Berdine HJ, et al. Management of chronic nonmalignant pain with nonsteroidal antiinflammatory drugs. Joint opinion statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2008;28:788-805.
112. Taylor RS, Fritzell P, Taylor RJ. Balloon kyphoplasty in the management of vertebral compression fractures: an updated systematic review and meta-analysis. Eur Spine J. 2007;16:1085-1100.
113. Hadjipavlou AG, Tzermiadianos MN, Katonis PG, et al. Percutaneous vertebroplasty and balloon kyphoplasty for the treatment of osteoporotic vertebral compression fractures and osteolytic tumours. J Bone Joint Surg Br. 2005;87:1595-1604.
114. Lieberman I, Reinhardt MK. Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop Relat Res. 2003;(415 suppl): S176-S186.
115. Krames ES. Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage. 1993;8:36-46.
116. Ghafoor VL, Epshteyn M, Carlson GH, et al. Intrathecal drug therapy for long-term pain management. Am J Health Syst Pharm. 2007;64: 2447-2461.
117. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin Pharmacother. 2008;9:1575-1583.
118. Wallace MS, Rauck R, Fisher R, et al. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg. 2008;106:628-637, table of contents.
119. Ely CA, Arregui ME. The use of enteral stents in colonic and gastric outlet obstruction. Surg Endosc. 2003;17:89-94.
120. Dormann AJ, Deppe H, Wigginghaus B. Self-expanding metallic stents for continuous dilatation of benign stenoses in gastrointestinal tract- first results of long-term follow-up in interim stent application in pyloric and colonic obstructions. Z Gastroenterol. 2001;39:957-960.
121. Nagele U, Kuczyk MA, Horstmann M, et al. Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis. World J Urol. 2008;26:257-262.
122. Acupuncture. NIH Consens Statement. 1997;15:1-34.
123. Birch S, Jamison RN. Controlled trial of Japanese acupuncture for chronic myofascial neck pain: assessment of specific and nonspecific effects of treatment. Clin J Pain. 1998;14:248-255.
124. NIH Consensus Conference. Acupuncture. JAMA. 1998;280:1518-1524.
125. Audette JF, Blinder RA. Acupuncture in the management of myofascial pain and headache. Curr Pain Headache Rep. 2003;7:395-401.
126. Day JA, Mason RR, Chesrown SE. Effect of massage on serum level of beta-endorphin and beta-lipotropin in healthy adults. Phys Ther. 1987;67:926-930.
127. Andersen BL. Psychological interventions for cancer patients to enhance the quality of life. J Consult Clin Psychol. 1992;60:552-568.
128. Billhult A, Dahlberg K. A meaningful relief from suffering experiences of massage in cancer care. Cancer Nurs. 2001;24:180-184.
129. Bunce IH, Mirolo BR, Hennessy JM, et al. Post-mastectomy lymphoedema treatment and measurement. Med J Aust. 1994;161:125-128.
130. Cassileth BR, Vickers AJ. Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage. 2004;28:244-249.
131. Ferrell-Torry AT, Glick OJ. The use of therapeutic massage as a nursing intervention to modify anxiety and the perception of cancer pain. Cancer Nurs. 1993;16:93-101.
132. Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. J Behav Med. 1985;8:163190.
133. Morley S, Eccleston C, Williams A. Systematic review and metaanalysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain. 1999;80:1-13.
134. Plews-Ogan M, Owens JE, Goodman M, et al. A pilot study evaluating mindfulness-based stress reduction and massage for the management of chronic pain. J Gen Intern Med. 2005;20:1136-1138.
135. Sellick SM, Zaza C. Critical review of 5 nonpharmacologic strategies for managing cancer pain. Cancer Prev Control. 1998;2:7-14.
136. Smith JE, Richardson J, Hoffman C, et al. Mindfulness-Based Stress Reduction as supportive therapy in cancer care: systematic review. J Adv Nurs. 2005;52:315-327.
137. Tsao JC. Effectiveness of massage therapy for chronic, non-malignant pain: a review. Evid Based Complement Alternat Med. 2007;4:165-179.
138. Weinrich SP, Weinrich MC. The effect of massage on pain in cancer patients. Appl Nurs Res. 1990;3:140-145.
139. Kutner JS, Smith MC, Corbin L, et al. Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med. 2008;149:369-379.